Randomised Controlled Trial to Assess Whether Computed Tomography Cardiac Angiography Can Improve Invasive Coronary Angiography in Bypass Surgery Patients
Launched by QUEEN MARY UNIVERSITY OF LONDON · Nov 7, 2018
Trial Information
Current as of April 25, 2025
Unknown status
Keywords
ClinConnect Summary
The BYPASS-CTCA trial is a single-centre, randomised controlled trial, which plans to recruit 688 patients who have had previous bypass grafts and require invasive coronary angiography over a period of 30 months.
Patients will be randomised to receive either computed tomography cardiac angiography (CTCA) prior to their invasive coronary angiogram, or invasive coronary angiography alone.
The primary endpoints will be the incidence of contrast induced nephropathy, the duration of the invasive coronary angiographic procedure and patient satisfaction. A number of secondary endpoints will also...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients undergoing invasive coronary angiogram +/- percutaneous coronary Intervention
- • 2. Previous Coronary Artery Bypass Grafting (CABG)
- • 3. Aged ≥18
- • 4. Patients able and willing to give their written informed consent.
- Exclusion Criteria:
- • 1. Subjects presenting with ST elevation myocardial infarction, cardiogenic shock (systolic blood pressure \<80 mmHg for \>30 minutes, or requiring inotropes or emergency intra aortic balloon pump for hypotension treatment) or cardiopulmonary resuscitation.
- • 2. Subjects with eGFR \<20ml/min or on renal replacement therapy.
- • 3. Current life-threatening condition other than vascular disease that may prevent a subject completing the study.
- • 4. Clinical instability including cardiogenic shock, hypotension (low blood pressure-systolic blood pressure less than 90 mmHg), sustained ventricular or atrial arrhythmia requiring intravenous medications.
- • 5. Inability to tolerate beta-blockers, including those with chronic obstructive pulmonary disease or asthma, complete heart block, second-degree atrioventricular block
- • 6. Known contrast dye allergy.
- • 7. Pregnancy or unknown pregnancy status.
- • 8. Patients considered unsuitable to participate by the research team (e.g., due to medical reasons, laboratory abnormalities, or subject's unwillingness to comply with all study related procedures).
- • 9. Inability or refusal to provide informed consent.
- • 10. Any inclusion criteria not met
Trial Officials
Daniel Jones, MRCP, PhD
Principal Investigator
Queen Mary University of London
About Queen Mary University Of London
Queen Mary University of London is a prestigious research-intensive institution recognized for its commitment to advancing medical science and improving health outcomes. As a leading sponsor of clinical trials, the university harnesses its academic excellence and innovative research capabilities to explore groundbreaking treatments and therapies across various medical disciplines. With a focus on collaboration, the institution engages with a diverse network of clinicians, researchers, and industry partners to ensure rigorous study design, ethical conduct, and the translation of research findings into clinical practice. Queen Mary University of London is dedicated to contributing to the global body of knowledge in healthcare through high-quality clinical research that prioritizes patient safety and welfare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials